The study used data on 399 infants born extremely preterm and surviving to 40 weeks postmenstrual age; 225 infants (56%) had no ROP treatment, while 145 (36%) and 29 (7%) had laser or anti-VEGF as their first ROP treatment, respectively. Here, VEGFA is linked to retinopathy of prematurity.